SHL has partnered with Swiss CDMO ten23 to offer services to firms requiring sterile drug/device combination products.

Shreeyashi Ojha, Reporter

March 28, 2024

2 Min Read
DepositPhotos/ivelin

Through this partnership the firms plan to integrate contract development and manufacturing organization (CDMO) ten23's capabilities with SHL Medical's autoinjector device technology. To support customers, this partnership will guide them through every step of the journey, from initial drug development to the successful commercialization of specific drug/device combination products.

The collaboration will support customers from pharma and biotech companies by integrating offerings from formulation development to final testing.

“Our motivation is to benefit our joint pharmaceutical and biotech customers and their patients by providing safe, effective, high quality and easily usable patient-centric and patient-friendly services and products,” Hanns-Christian, CEO of ten23 told BioProcess Insider.

“Customers in pharma and biotech may struggle to identify appropriate service providers offering different services (such as development - manufacturing- assembly - testing) and component providers (such as primary packaging and devices). Through our combined offerings, customers can have peace of mind and benefit from derisked development and optimal timelines.”

Emphasizing patient-centricity as the “key to this collaboration,” the partnership will target usability and patient experience as an important outcome of the various components of the final product including its formulation, choice of primary packaging components like syringe and needle, definition and characterization of process parameters for filling, and choice of integration with the device.

Highlighting the key services provided through this collaboration, the CEO added, “ten23’s formulation and process development, GMP fill & finish of syringes and cartridges, final assembly of autoinjectors and needle-safety devices, product testing and quality check (QC), while SHL provides its autoinjector device technology like its flagship platform Molly.”

According to SHL, its Molly platform offers a cost-effective and low-risk solution helping pharma and biotech companies reduce initial investments and expedite development timelines. It is a modular platform designed for flexible and scalable production, assembly, and final product testing.

The financials associated with this partnership have not been disclosed.

About the Author(s)

Shreeyashi Ojha

Reporter, BioProcess Insider

Journalist covering the manufacturing and processing sectors for biopharmaceuticals globally.  

Originally from India, I am a Londoner at heart. I have recently graduated from Goldsmiths, University of London.  

Feel free to reach out to me at: [email protected].

You May Also Like